Filing Flows › iSpecimen (ISPC) › Q2 2026
iSpecimen (ISPC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
iSpecimen (ISPC) reported revenue of $152K for the second quarter 2026 (Q2 2026), -79% from a year earlier and -3% from the quarter before. Operating margin was -897.1%, net loss $1.4M (896.9% of revenue).
iSpecimen, Q2 2026: revenue $152K (-79% year over year), operating margin -897.1%, net loss $1.4M, operating cash flow −$690K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $152K | -3% | -79% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | −$690K | — | — |
What changed
Revenue was $152K in Q2 2026, down 79% year over year and down 3% from the previous quarter. Product was the largest line at 83% of revenue. Product lost $546K year over year (down 81%), 97% of the total change.
Operating costs exceeded revenue by $1.4M, an operating margin of -897.1%. Total costs fell 40% while revenue fell 79%. The fastest-growing cost line was Sales & marketing (+111%). The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $2.3M loss.
Operating cash flow was −$690K. Non-cash charges added back $201K of depreciation and amortization and $0K of share-based compensation. Working capital and other items added $472K.
Questions
What was iSpecimen's revenue in the second quarter 2026?
iSpecimen (ISPC) reported revenue of $152K for the second quarter 2026 (Q2 2026), -79% from a year earlier and -3% from the quarter before.
Was iSpecimen profitable in the second quarter 2026?
Operating loss was $1.4M (-897.1% of revenue) and net loss $1.4M.
Source: iSpecimen 10-Q on SEC EDGAR.